Weitao Biotech completed over 100 million yuan in angel round financing, led by Qiming Venture Partners.
Recently, Microtide Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as "Microtide Bio"), an innovative enterprise in the global in - vivo cell therapy field, announced the completion of an angel - round financing exceeding 100 million RMB. This round of financing was led by Qiming Venture Partners, a globally leading venture capital institution. The financing funds will be mainly used for the iterative optimization of the core technology platform and the clinical translation and development of the first candidate product in the field of autoimmune diseases.
Microtide Bio was established on June 25, 2025, and was spun off from the in - vivo CAR - T platform of Beijing Shali Biomedical Co., Ltd. (hereinafter referred to as "Shali Bio"). Microtide Bio's in - vivo CAR - T therapy, based on the targeted LNP delivery system, focuses on bringing innovative treatment methods for hematological tumors and autoimmune diseases. It can directly complete the expression of CAR in the patient's T cells. Patients do not need to go through the processes of cell separation, expansion, and lymphodepletion pretreatment in traditional autologous CAR - T therapy, fundamentally solving the three core pain points of "high cost, long cycle, and high toxicity" in autologous CAR - T therapy. It is expected to significantly shorten the treatment process cycle, realize the evolution of cell therapy into off - the - shelf drugs, and greatly improve patient accessibility.
Meanwhile, Microtide Bio's targeted LNP - based delivery system performs outstandingly in terms of precision, safety, and production compatibility. It improves the T - cell targeting efficiency through a unique technical path, effectively reduces the off - target risk, and is suitable for large - scale production; The self - developed targeting technology can achieve efficient activation of T cells and long - term expression of CAR. It has excellent B - cell clearance effects in multiple pre - clinical models and good safety in repeated dosing. The first candidate product has entered the clinical stage, and positive preliminary human data have been obtained.
As the leading investor in this round, Qiming Venture Partners has long been deeply involved in the field of medical innovation. In the field of cutting - edge technologies, Qiming Venture Partners focuses on cutting - edge technology directions such as cell therapy and gene delivery. Dr. Chen Kan, a partner at Qiming Venture Partners and co - head of the medical innovation industry, said: "Microtide Bio's technical solution solves the technical challenges of traditional CAR - T therapy. Its targeted LNP delivery platform shows global leading potential in terms of targeting efficiency, safety, and production compatibility. We are optimistic about Dr. Liu Yarong's team's industrialization experience in the field of cell therapy and the guarantee of R & D efficiency by Shali Bio's FTE model. We will rely on global industrial resources to help Microtide Bio accelerate clinical progress and international cooperation, and promote Chinese innovative drugs to gain an advantage globally."
Dr. Liu Yarong, the founder and CEO of Microtide Bio, said: "Thanks to the trust of Qiming Venture Partners and other investors. As a deep - rooted player in the Chinese cell therapy field, our team has always been committed to filling the unmet clinical needs through technological innovation. Microtide Bio's in - vivo CAR - T solution is an important step in promoting the development of cell therapy towards 'off - the - shelf' and 'accessible' directions. This round of financing will accelerate the clinical verification of Microtide Bio and its in - vivo CAR - T pipeline. In the future, we will continue to adhere to the concept of 'insight into needs and independent innovation' and strive to bring more innovative treatment methods to patients."
This article is from the WeChat official account "Qiming Venture Partners", and is published by 36Kr with authorization.